Literature DB >> 2855309

Identification of nanopeptide from HTLV-III, ARV-2 and LAVBRU envelope gp120 determining binding to T4 cell surface protein.

V Veljković1, R Metlas.   

Abstract

The information contained in the primary structure of HIV envelope gp120 determining its biological activity, was analyzed by the use of the informational spectrum method. The parameter determining the interaction between gp120 and T4 cell-surface protein was defined. On the basis of this data in the conserved region of gp120 from HTLV-III, LAVBRU and ARV-2, a nanopeptide NAKTIIVQL was identified as a potential binding domain which could be used as a component of an effective therapeutic agent or as a vaccine component.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2855309

Source DB:  PubMed          Journal:  Cancer Biochem Biophys        ISSN: 0305-7232


  5 in total

1.  Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.

Authors:  Sanja Glisic; Nevena Veljkovic; Snezana Jovanovic Cupic; Nada Vasiljevic; Jelena Prljic; Branislava Gemovic; Vladimir Perovic; Veljko Veljkovic
Journal:  Protein J       Date:  2012-02       Impact factor: 2.371

2.  Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection.

Authors:  Veljko Veljkovic; Slobodan Paessler
Journal:  F1000Res       Date:  2016-02-18

3.  Antibody Epitope Specificity for dsDNA Phosphate Backbone Is an Intrinsic Property of the Heavy Chain Variable Germline Gene Segment Used.

Authors:  Tatjana Srdic-Rajic; Heinz Kohler; Vladimir Jurisic; Radmila Metlas
Journal:  Front Immunol       Date:  2018-10-18       Impact factor: 7.561

4.  The EMILIN/Multimerin family.

Authors:  Alfonso Colombatti; Paola Spessotto; Roberto Doliana; Maurizio Mongiat; Giorgio Maria Bressan; Gennaro Esposito
Journal:  Front Immunol       Date:  2012-01-06       Impact factor: 7.561

5.  Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control.

Authors:  Veljko Veljkovic; Nevena Veljkovic; Claude P Muller; Sybille Müller; Sanja Glisic; Vladimir Perovic; Heinz Köhler
Journal:  BMC Struct Biol       Date:  2009-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.